Abstract
In one of the largest biotech debuts this year, Neumora Therapeutics has raised $400 million in series A financing from more than a dozen venture capital firms, plus $100 million from Amgen. The firm’s goal: precision small-molecule therapies for a multitude of brain diseases. The start-up was quietly founded in late 2019 by several people at Arch Venture Partners, neurobiologist Morgan Sheng of Broad Institute of MIT and Harvard, and others. The company has since grown to a team of 90 people based at sites just outside Boston and San Francisco. Neumora has acquired four smaller start-ups that will help it hit the ground running. It has eight drug programs, plus a research collaboration with Amgen on additional programs for brain diseases including amyotrophic lateral sclerosis and schizophrenia. CEO and cofounder Paul L. Berns says the company is based on advances in neuroscience disease biology and computational data science. Neumora
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
